GAD alum treatment delayed onset of stage 3 type 1 diabetes in autoantibody-positive children with HLA-DR3-DQ2. The findings support treatment based on genetic risk and highlight the need for further studies of GAD alum #T1D #Diabetes link.springer.com/article/10.1... 🔓
Delayed time to stage 3 type 1 diabetes after GAD-alum treatment in HLA-DR3-DQ2-positive children: follow-up of the randomised placebo-controlled Diabetes Prevention – Immune Tolerance trial - Diabeto...
Aims/hypothesis The aim of this study was to assess the long-term treatment effects of alum-formulated human recombinant GAD65 (GAD-alum) after completion of the Diabetes Prevention – Immune Tolerance...
link.springer.com